Skip to main content

Chronic Obstructive Airway Disease

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
1
Tiotropium 'Respimat' 5 mcgPhase 4
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Tiotropium 'Respimat' 5 mcgPhase 41 trial
Active Trials
NCT03275116Unknown49Est. Dec 2020
Synapse Biomedical
Synapse BiomedicalOH - Oberlin
1 program
NeuRx Diaphragm Pacing SystemN/A1 trial
Active Trials
NCT02411383Completed4Est. Apr 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstraZenecaTiotropium 'Respimat' 5 mcg
Synapse BiomedicalNeuRx Diaphragm Pacing System

Clinical Trials (2)

Total enrollment: 53 patients across 2 trials

NCT03275116AstraZenecaTiotropium 'Respimat' 5 mcg

The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.

Start: Jul 2017Est. completion: Dec 202049 patients
Phase 4Unknown
NCT02411383Synapse BiomedicalNeuRx Diaphragm Pacing System

Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation

Start: Feb 2015Est. completion: Apr 20164 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.